| abstract |
Controlled-release formulations providing a "pulsed" plasma profile of a sedative-hypnoticncompounds having a particularly short half-life are provided. The formulation contains ansedative-hypnotic compound or precursor thereof that is metabolized to generate a sedative-hypnoticncompound in vivo, wherein the compound has a mean plasma half life ranging fromn0.1 to 2 hours; and at least one release retardant such that, following administration of thenformulation to a patient, the patient has specific pulsed plasma profile for the sedative-hypnoticncompound as disclosed herein. In a preferred embodiment, the sedative-hypnoticncompound is NBI-34060. |